Ibex Biosciences

Ibex Biosciences is a private, pre-clinical biotech firm pursuing a multi-platform strategy in antibodies, gene therapy, and regenerative medicine. The company leverages its internal discovery capabilities, highlighted by its CSO's background in phage display technology, to build a wholly-owned pipeline targeting oncology, infectious disease, and inflammatory conditions. Currently in a pre-revenue stage, Ibex is actively seeking investment through a Regulation D 506(c) offering to advance its programs. Its management team brings decades of experience in preclinical research, gene therapy, and business development.

Internal discovery capabilities including peptide phage display for antibody discovery and recombinant viral vector development for gene therapy. Focus on novel molecule and delivery method identification.

Ibex competes in intensely crowded fields. Its oncology ADC work faces competition from large pharma and specialized biotechs. The gene therapy space is dominated by well-funded players with advanced platforms. Differentiation will require demonstrating superior efficacy or novel mechanisms from its internal discoveries.